Physician profile
Layne E Subera
NPI 1568483758
$2,583.95
in general payments reported to CMS, 2019-2025
17 companies · $601 in 2025
The $601 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $274 · 2021: $155 · 2022: $324 · 2023: $266 · 2024: $682 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,548.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $990.12 | 2021-2025 | Vraylar |
| Allergan, INC. | $385.00 | 2019-2020 | |
| Indivior INC. | $229.70 | 2019-2024 | Sublocade |
| Braeburn INC. | $189.78 | 2023-2025 | Brixadi |
| Amgen INC. | $132.35 | 2020-2023 | Otezla |
| Janssen Pharmaceuticals, INC | $97.83 | 2021-2024 | Spravato |
| Edwards Lifesciences Corporation | $94.86 | 2024 | |
| Boston Scientific Corporation | $91.91 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $89.87 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $87.44 | 2024-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $45.75 | 2022-2024 | Ingrezza |
| Abiomed | $43.42 | 2024 | Impella |
| Alkermes, INC. | $32.02 | 2024-2025 | Vivitrol |
| Vanda Pharmaceuticals INC. | $25.75 | 2024 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.22 | 2023 | Jardiance |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $14.96 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $12.97 | 2023 | Trelegy Ellipta, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Layne Subera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.